Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 NICE's 2008 Methods Guide: sensible consolidation or opportunities missed?

× No keyword cloud information.

11 in total

1. A comparison of the Assessment of Quality of Life (AQoL) with four other generic utility instruments.

Authors: G Hawthorne; J Richardson; N A Day
Journal: Ann Med Date: 2001-07 Impact factor: 4.709

2. Coverage options for promising technologies: Medicare's 'coverage with evidence development'.

Authors: Sean R Tunis; Steven D Pearson
Journal: Health Aff (Millwood) Date: 2006 Sep-Oct Impact factor: 6.301

3. Coverage with evidence development: an examination of conceptual and policy issues.

Authors: John Hutton; Paul Trueman; Christopher Henshall
Journal: Int J Technol Assess Health Care Date: 2007 Impact factor: 2.188

4. NICE Methodology for Technology Appraisals: cutting edge or tried and trusted?

Authors: Louise Longworth; Carole Longson
Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981

5. Estimating 'costs' for cost-effectiveness analysis.

Authors: Alec Miners
Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981

Review 6. The NICE cost-effectiveness threshold: what it is and what that means.

Authors: Christopher McCabe; Karl Claxton; Anthony J Culyer
Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981

Review 7. Use of indirect and mixed treatment comparisons for technology assessment.

Authors: Alex Sutton; A E Ades; Nicola Cooper; Keith Abrams
Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981

8. Exploring uncertainty in cost-effectiveness analysis.

Authors: Karl Claxton
Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981

Review 9. Valuing health States for use in cost-effectiveness analysis.

Authors: John Brazier
Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981

10. Subgroups and heterogeneity in cost-effectiveness analysis.

Authors: Mark Sculpher
Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981

6 in total

1. Economic evaluation and cost-effectiveness thresholds: signals to firms and implications for R & D investment and innovation.

Authors: John A Vernon; Robert Goldberg; Joseph Golec
Journal: Pharmacoeconomics Date: 2009 Impact factor: 4.981

2. The use of a Cumulative Needs for Care Monitor for individual treatment v. care as usual for patients diagnosed with severe mental illness, a cost-effectiveness analysis from the health care perspective.

Authors: M Drukker; M Joore; J van Os; S Sytema; G Driessen; M Bak; Ph Delespaul
Journal: Epidemiol Psychiatr Sci Date: 2012-05-22 Impact factor: 6.892

3. An economic evaluation of a video- and text-based computer-tailored intervention for smoking cessation: a cost-effectiveness and cost-utility analysis of a randomized controlled trial.

Authors: Nicola E Stanczyk; Eline S Smit; Daniela N Schulz; Hein de Vries; Catherine Bolman; Jean W M Muris; Silvia M A A Evers
Journal: PLoS One Date: 2014-10-13 Impact factor: 3.240

4. Cost-effectiveness and cost-utility of a Web-based or print-delivered tailored intervention to promote physical activity among adults aged over fifty: an economic evaluation of the Active Plus intervention.

Authors: Rianne Hj Golsteijn; Denise A Peels; Silvia Maa Evers; Catherine Bolman; Aart N Mudde; Hein de Vries; Lilian Lechner
Journal: Int J Behav Nutr Phys Act Date: 2014-09-28 Impact factor: 6.457

5. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.

Authors: Elena Nicod
Journal: Eur J Health Econ Date: 2016-08-18

6. Cost-effectiveness and cost-utility of Internet-based computer tailoring for smoking cessation.

Authors: Eline Suzanne Smit; Silvia M A A Evers; Hein de Vries; Ciska Hoving
Journal: J Med Internet Res Date: 2013-03-14 Impact factor: 5.428

6 in total